MUC1 in carcinoma-host interactions

被引:30
作者
Denda-Nagai, K [1 ]
Irimura, T [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan
关键词
MUC1; mucin; genetic polymorphism; O-glycosylation; tumor marker; cell adhesion; cancer immunotherapy;
D O I
10.1023/A:1011039013134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Many carcinoma-associated markers are glycoconjugates whose expression undergoes temporal or spatial regulation. Mucin-1 (MUC1), discovered through monoclonal antibody technology, is a well-documented example of such a molecule and influences numerous pathophysiological behaviors, such as the invasion and metastasis of carcinoma cells. Levels of MUC1 expression in carcinomas correlate with the clinical stage of the cancer and inversely correlate with the survival prospects of patients. The MUC1 immune response is known to provide a protective host defense mechanism against cancer. The multiple functions of MUC1 in carcinoma-host interactions are believed to be dependent on the polymorphic nature of MUC1, particularly its glycosylation status.
引用
收藏
页码:649 / 658
页数:10
相关论文
共 112 条
[1]
MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines [J].
Acres, B ;
Apostolopoulos, V ;
Balloul, JM ;
Wreschner, D ;
Xing, PX ;
Ali-Hadji, D ;
Bizouarne, N ;
Kieny, MP ;
McKenzie, IFC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) :588-594
[2]
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].
Agrawal, B ;
Krantz, MJ ;
Reddish, MA ;
Longenecker, BM .
NATURE MEDICINE, 1998, 4 (01) :43-49
[3]
Agrawal B, 1998, CANCER RES, V58, P4079
[4]
Agrawal B, 1996, J IMMUNOL, V157, P2089
[5]
MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral [J].
Apostolopoulos, V ;
Osinski, C ;
McKenzie, IFC .
NATURE MEDICINE, 1998, 4 (03) :315-320
[6]
APOSTOLOPOULOS V, 1994, CANCER RES, V54, P5186
[7]
APOSTOLOPOULOS V, 1995, J IMMUNOL, V155, P5089
[8]
BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537
[9]
BAECKSTROM D, 1993, CANCER RES, V53, P755
[10]
BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430